Mes: abril 2020

IDTechEx Research: Hot Performance and Cool Operation for Electric Vehicle Motors

BOSTON, April 2, 2020 /PRNewswire/ — The market for electric vehicles is set to exceed $1,000bn by 2030 but potential consumers are still concerned with range, cost and safety. Whilst this draws attention initially to the battery, an equally important factor and unifying component of electric vehicles is the electric motor and its effective thermal management. The electric motor is responsible for…

BOSTON, April 2, 2020 /PRNewswire/ — The market for electric vehicles is set to exceed $1,000bn by 2030 but potential consumers are still concerned with range, cost and safety. Whilst this draws attention initially to the battery, an equally important factor and unifying component of electric vehicles is the electric motor and its effective thermal management. The electric motor is responsible for driving the vehicle and different manufacturers take varying approaches to accomplish this. Many manufacturers, especially in China utilise permanent magnet motors for their impressive power and torque density, but these can be susceptible to price hikes in rare-earth materials. For this reason, some OEMs have utilised induction motors or wound rotor motors eliminating the need for rare-earths. However, a popular trend going forward appears to be the adoption of permanent magnet motors using fewer rare-earths such as the new Honda e. Companies ranging from international giants to start-ups have announced the release of fluids specific to electric vehicle motors including Petronas, Shell and Total, to name a few.

 

Electric passenger cars using permanent magnets in their motor vs other motor designs, with a dominant and steadily increasing shift towards permanent magnets, a significant portion of this trend is due to Tesla shifting away from induction for the Model 3. Source: IDTechEx report “Thermal Management for Electric Vehicles 2020-2030” including a full breakdown of motor type 2015-2019. (www.IDTechEx.com/TMEV)

 

Regardless of motor choice, all types of motor generate heat and dispersing this heat is critical, increased temperature of copper windings results in a raised resistance and a reduced efficiency. A motor not operating efficiently can significantly harm the performance and potential range of the vehicle. Permanent magnet motors also risk denaturing the magnetic material above a certain critical temperature rendering the motor useless. In addition to the above concerns, an overheating motor has the potential to damage neighbouring components, at best this can cause component failures and at worst a full-blown fire.

In addition to the type of motor used the cooling mechanism also varies between manufacturers and application. In smaller more open vehicles such as electric motorbikes often a suitably engineered air-cooled motor will suffice, whereas in many electric car applications water-glycol coolant is passed through a jacket around the motor. Oil injected into the motor itself is also a popular option to maintain optimal operating temperatures and lubrication, but a large factor going forward is how the cooling system can interact with the rest of the thermal management strategies in the vehicle. If the same coolant can be used for the batteries and motors, then this can reduce the complexity and cost of a system, plus excess heat from the motor can potentially be used to heat the batteries or passenger cabin when in cold ambient conditions.

Looking to replace the above currently used strategies are emerging alternative technologies such as refrigerant cooling, phase change materials or even dielectric immersion. How these evolve will depend on motor type, construction and composition. As manufacturers stop retrofitting internal combustion vehicles and start creating vehicles specifically designed to be electric, some strategies may prevail whilst some fade, and potential for new emerging routes present themselves.

The current and emerging thermal management strategies for electric motors is just one aspect of IDTechEx’s latest report on «Thermal Management for Electric Vehicles 2020-2030«. Batteries and power electronics are also extremely important when considering the thermal management of a vehicle, with varying approaches taken by OEMs with some trends in progress and some expected in the future, these strategies and future trends are also covered in this latest report.

To find out more about electric vehicle research available from IDTechEx visit www.IDTechEx.com/research/EV or to connect with others on this topic, IDTechEx Events is hosting: Electric Vehicles – Everything is changing, November 18-19 2020, Santa Clara, USA www.IDTechEx.com/EVUSA.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact research@IDTechEx.com or visit www.IDTechEx.com.

Photo – https://mma.prnewswire.com/media/1141029/IDTechEx.jpg
Logo – https://mma.prnewswire.com/media/478371/IDTechEx_Logo.jpg

Media Contact:

Jessica Abineri
Marketing Coordinator
press@IDTechEx.com
+44(0)1223 812300

 

IDTechEx Logo

 

La FDA solicita el retiro del mercado de todos los productos hechos a base de ranitidina (Zantac)

La FDA alerta a los consumidores, pacientes y profesionales de la salud después de que nuevos estudios realizados por la FDA muestran riesgos a la salud pública

In English

SILVER SPRING, Md., 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — La…

La FDA alerta a los consumidores, pacientes y profesionales de la salud después de que nuevos estudios realizados por la FDA muestran riesgos a la salud pública

In English

SILVER SPRING, Md., 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — La Administración de Alimentos y Medicamentos de los EE.UU. anunció hoy que les está solicitando a los fabricantes que retiren del mercado inmediatamente todos los medicamentos recetados y de venta libre hechos a base de ranitidina. Esta es la más reciente medida de una investigación en curso de una impureza conocida como N-nitrosodimetilamina (NDMA, por sus siglas en inglés) en medicamentos hechos a base de ranitidina (comúnmente conocidos por el nombre de marca  Zantac). La agencia ha determinado que la impureza en algunos productos hechos a base de ranitidina aumenta con el tiempo y cuando se almacena a temperaturas superiores a la temperatura ambiente, y puede resultar en la exposición de los consumidores a niveles inaceptables de esta impureza. Como resultado de esta solicitud de retiro inmediato del mercado, los productos hechos a base de ranitidina no estarán disponibles para recetas nuevas o existentes, o medicamentos de venta libre en los EE.UU.  

«La FDA está comprometida a asegurar que los medicamentos que los estadounidenses ingieren sean seguros y eficaces. Hacemos el máximo esfuerzo para investigar los posibles riesgos a la salud y ofrecer nuestras recomendaciones al público basándonos en los mejores conocimientos científicos disponibles. No observamos niveles inaceptables de NDMA en muchas de las muestras que analizamos. Sin embargo, como no sabemos cómo o por cuánto tiempo el producto puede haber estado almacenado, decidimos que no debe estar disponible para los consumidores y pacientes a menos que se pueda asegurar su calidad,» dijo Janet Woodcock, M.D., Directora del Centro de evaluación e investigación de medicamentos de la FDA. La FDA continuará con sus esfuerzos para asegurar que las impurezas en otros medicamentos no excedan los límites aceptables para que los pacientes puedan continuar tomando sus medicamentos sin preocupación.»

La NDMA es probablemente un agente cancerígeno humano (una sustancia que puede causar cáncer). Durante el verano de 2019, la FDA tomó consciencia de pruebas por parte de laboratorios independientes que encontraron NDMA en la ranitidina. Bajos niveles de NDMA son ingeridos comúnmente en la dieta; por ejemplo, la NDMA está presente en alimentos y el agua. No se espera que estos bajos niveles den lugar a un aumento en el riesgo de cáncer. Sin embargo, niveles de exposición continuos más altos pueden aumentar el riesgo de cáncer en humanos. La FDA realizó pruebas de laboratorio exhaustivas y encontró bajos niveles de la NDMA en la ranitidina. En ese momento, la agencia no tenía suficiente evidencia científica para recomendarles a los consumidores que continuaran tomando o que dejaran de tomar los medicamentos hechos a base de ranitidina, continuó con la investigación  y alertó al público en septiembre de 2019 de los posibles riesgos y a que considerara tratamientos de venta libre o recetados alternativos.  

Las nuevas pruebas y análisis realizados por la FDA, impulsados por los laboratorios de terceras partes, confirmaron que los niveles de ranitidina aumentan incluso bajo condiciones de almacenaje normales, y se encontró que los niveles de  la NDMA aumentan considerablemente en las muestras que se almacenan a temperaturas superiores, incluyendo las temperaturas a las que el producto puede ser expuesto durante su distribución y manejo de los consumidores.  Las pruebas también mostraron que a medida que el producto a base de ranitidina envejece, o que el periodo de tiempo desde  que fue fabricado se alarga, más alto es el nivel de la NDMA. Estas condiciones pueden elevar el nivel de la NDMA en el producto hecho a base de ranitidina sobre el nivel de ingesta diaria aceptable.  

Con el aviso de hoy, la FDA está enviando cartas a todos los fabricantes de productos hechos a base de ranitidina solicitando que retiren sus productos del mercado. La FDA también está alertando a los consumidores que toman productos hechos a base de ranitidina de venta libre a que dejen de tomar las tabletas o líquido que tengan en casa, los desechen de forma adecuada y no los compren más; los consumidores que deseen continuar tratando su condición, deben considerar el uso de otros productos de venta libre aprobados. Los pacientes que toman productos hechos a base de ranitidina recetados deben hablar con su profesional de atención médica sobre otras opciones de tratamiento antes de dejar de tomar el medicamento, ya que hay varios medicamentos aprobados para el mismo uso o uso similar como los productos hechos a base de ranitidina que no tienen los mismos riesgos debido a la NDMA. Hasta la fecha, las pruebas de la FDA no han encontrado la NDMA en famotidina (Pepcid), cimetidina (Tagamet), esomeprazol (Nexium), lansoprazol (Prevacid) u omeprazol (Prilosec).

Ante la pandemia actual del COVID-19, la FDA les recomienda a los pacientes y consumidores que no lleven sus medicamentos a un lugar que acepte devoluciones, sino que sigan las instrucciones específicas de desecho en la guía del medicamento o el folleto adjunto o que sigan las medidas que la agencia recomienda, las cuales incluyen maneras para desechar de manera segura en casa estos medicamentos. 

La FDA continúa la revisión, vigilancia y cumplimiento en curso y los esfuerzos para asegurar la calidad farmacéutica de todos los sectores de productos, y continuará trabajando con los fabricantes de medicamentos para asegurar medicamentos seguros, eficaces y de alta calidad para el público estadounidense. 

La FDA alienta a los profesionales de atención médica y a los pacientes a reportar reacciones adversas o problemas de calidad con cualquier medicamento para humanos al programa sobre reportes de la agencia: Reportando eventos adversos MedWatch:

La FDA, una agencia que es parte del Departamento de Salud y Servicios Humanos de los EE.UU., protege la salud pública al asegurar la seguridad, eficacia y protección de los medicamentos humanos y veterinarios, vacunas y otros productos biológicos para el uso humano, y los dispositivos médicos. La agencia también es responsable de la seguridad del suministro de alimentos, cosméticos, suplementos alimenticios, y de los productos que emiten radiación electrónica de nuestra nación, y de regular los productos de tabaco.

Información para los medios de comunicación: Gloria Sánchez-Contreras, 301-796-7686, gloria.sanchez-contreras@fda.hhs.gov 
Información al consumidor: 888-INFO-FDA
www.FDA.gov/Espanol 

U.S. Food and Drug Administration (FDA) logo

Logo – http://mma.prnewswire.com/media/622604/FDA_Logo.jpg

FUENTE U.S. Food and Drug Administration

March of Dimes Encourages People to Step Up! to Support Moms and Babies during the COVID-19 Pandemic

ARLINGTON, Virginia, April 2, 2020 /PRNewswire-HISPANIC PR WIRE/ — March of Dimes today launched a new virtual campaign, called Step Up!, to…

ARLINGTON, Virginia, April 2, 2020 /PRNewswire-HISPANIC PR WIRE/ — March of Dimes today launched a new virtual campaign, called Step Up!, to raise vital support for moms and babies during the COVID-19 pandemic causing the ongoing global health crisis. The new virtual fundraiser will replace this year’s March of Dimes’ annual in-person March for Babies events that for the past 50 years have seen thousands of people march as a way to fundraise. Due to social distancing and stay-in-place orders, March of Dimes is encouraging supporters across the country to Step Up! by taking part in a virtual walk – safely at home or wherever they can – in order to support moms and babies during their greatest time of need. 

March of Dimes Foundation Logo

«It is imperative that moms and babies have access to the care and resources required for a healthy start each and every day, and the need has become even more critical in our current environment,» said Stacey D. Stewart, President and Chief Executive Officer of March of Dimes. «During this unprecedented time, March for Babies Step Up! is so vitally important because through the incredible fundraising efforts of our supporters, we can continue to help moms and babies as well as learn more about this novel disease. We are so thankful our supporters are able to virtually participate in this innovative fundraising activity that will make a difference in the lives of families everywhere.»

Beginning today, March for Babies is asking participants to register to virtually march at marchforbabies.org. The virtual March for Babies will commence across the country with participants tracking their steps using smart phones or fitness watches and collecting donations for their steps. Every step will be tracked and totaled through the Charity Miles mobile app, culminating in a virtual celebration on May 15. Participants will also have the opportunity to engage in a series of fun, virtual challenges throughout the campaign to boost their step count, share personal stories about why they’re «stepping up» and ultimately raise awareness of the critical needs of mothers and babies right now.

«Expecting mothers can’t pause pregnancy. The COVID-19 pandemic is putting a strain on the healthcare system, and at this time, the health risks to moms and babies remain mostly unknown, however they are the ones who depend on the health system for support from pregnancy through delivery,» shared Dr. Rahul Gupta, Senior Vice President and Chief Medical and Health Officer at March of Dimes. «There is an urgent need, due to the COVID-19 pandemic, to support families with a baby in the Neonatal Intensive Care Unit (NICU) and ensure that moms-to-be have the latest health information to protect themselves and their infants.»

Even in the best of times, moms and babies rely on March of Dimes programs, research, advocacy and health information. There are families right now imagining preparing to labor or new parents concerned for their baby in the NICU, and that is why March for Babies will proceed, but in a new way.

«I believe the March of Dimes mission to support and protect moms and babies has never been more urgent than it is today and I’m honored to have been able to help kick off the Step Up! campaign through a virtual launch event last week,» shared Eli Manning, retired New York Giants Quarterback and New York City March for Babies Vice Chairman.  «March of Dimes is an organization built on the idea that when we come together, we can achieve great things. And, honestly this year’s March for Babies seemed unlikely, but we worked to develop a game plan, and the simple answer is – we will all ‘step up’ to help raise critical funds needed during this unprecedented time.»

For more than 80 years, March of Dimes has pioneered research, led programs, provided educational resources and enabled policy change so that every mom and baby can have the best possible start. The funds raised through Step Up! will continue to support research for COVID-19 treatments that are safe for pregnant and lactating moms, fundraising and advocacy efforts needed to help those families directly impacted by COVID-19, resources and training for doctors and nurses in the ICU and NICU, and the development of educational materials for moms-to-be and families about what they should know to protect themselves.

For more information on how to sign up to Step Up! and fundraise, please visit www.marchforbabies.org. To download the Charity Miles app, click here from your mobile device to download the Charity Miles App. Step along with us on Facebook, Instagram and Twitter, and share your journey using #MarchforBabies and #MFBStepUp!

About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every baby can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we empower every mom and every family. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.

Logo – https://mma.prnewswire.com/media/513643/March_of_Dimes_Foundation_Logo.jpg

Logo – https://mma.prnewswire.com/media/1140945/MFBStepUp_Logo.jpg

SOURCE March of Dimes

El Sistema de Hemodiálisis Tablo® recibe la aprobación de la FDA para diálisis hogareña

El primer dispositivo nuevo autorizado para hemodiálisis en el hogar en 15 años 

SAN JOSÉ, California, 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — Outset Medical, una compañía innovadora líder en tecnología médica que aporta tecnología primera en su tipo al creciente mercado global de diálisis, anunció hoy que la Administración de Alimentos y Fármacos de los EE. UU. (FDA por sus siglas en inglés) autorizó el Sistema de Hemodiálisis Tablo para uso de los pacientes en el hogar. La…

El primer dispositivo nuevo autorizado para hemodiálisis en el hogar en 15 años 

SAN JOSÉ, California, 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — Outset Medical, una compañía innovadora líder en tecnología médica que aporta tecnología primera en su tipo al creciente mercado global de diálisis, anunció hoy que la Administración de Alimentos y Fármacos de los EE. UU. (FDA por sus siglas en inglés) autorizó el Sistema de Hemodiálisis Tablo para uso de los pacientes en el hogar. La nueva autorización para uso hogareño amplía la indicación de uso ya existente en la etiqueta de Tablo para el uso en instalaciones para la atención aguda y crónica, y por primera vez habilita a los proveedores de atención médica a llevar la misma máquina de diálisis de la UCI al hogar.

Tablo ingresa al mercado en un momento crucial, en medio de la pandemia de COVID-19 y un foco nacional renovado en la diálisis en el hogar para mejorar la evolución de los pacientes y a la vez disminuir el costo. A mediados de 2019, el presidente Trump y el secretario del Departamento de Salud y Servicios Humanos de los Estados Unidos Alex Azar anunciaron un decreto ejecutivo para ayudar a los estadounidenses con insuficiencia renal. Un importante componente de la política fue asegurar que el 80% de todos los nuevos pacientes de diálisis iniciaran el tratamiento en su casa o recibieran un trasplante para 2025. La emergencia del COVID-19 eleva aún más la urgencia de darles a los pacientes de diálisis actualmente tratados en centros la opción del tratamiento en el hogar.

«Tablo fue diseñado para simplificar la diálisis, facilitarla y hacerla más accesible, a fin de que los pacientes aprovechen la seguridad, la conveniencia y la flexibilidad de dializarse en casa», comentó la CEO de Outset Medical, Leslie Trigg. «Nos enorgullece ofrecerles esta nueva opción que mejora la vida, particularmente a la luz de los desafíos relacionados con el COVID-19 que están experimentando los pacientes y proveedores de diálisis».

Actualmente, más de 500,000 estadounidenses se someten a tratamientos de diálisis tres o más veces por semana, que típicamente demoran cuatro horas por tratamiento. Aproximadamente 100,000 pacientes nuevos inician su tratamiento cada año. Sin embargo, solo 12% lo reciben en su casa, donde están más cómodos, productivos y empoderados.

RESULTADOS POSITIVOS EN EL ESTUDIO 

En 2019 se completó un estudio prospectivo multicéntrico de hemodiálisis hogareña con 30 pacientes, que confirmó que el sistema Tablo es seguro y efectivo para el uso en el hogar. Los resultados se publicaron en noviembre de 2019 en Hemodialysis International.

El Dr. Troy Plumb, investigador principal del estudio y jefe de División de Nefrología y profesor asociado de Medicina en la Facultad de Medicina del Centro Médico de la Universidad de Nebraska en Omaha, comentó: «Mis pacientes, colegas y yo estamos entusiasmados de que Tablo esté disponible para el uso hogareño. El estudio dejó en claro que el sistema es fácil de aprender y se desempeña bien en el entorno hogareño. Creo que Tablo abrirá oportunidades para que los pacientes procuren hemodiálisis en su casa y tomen más control sobre su vida y su atención».

Uno de esos pacientes es el residente de Texas y consultor en tecnología de 62 años, Richard Crawford. Tuvo un trasplante renal que duró 17 años, y actualmente está en la lista de espera para trasplante. A lo largo de los años se le han hecho miles de tratamientos de diálisis en diversos centros, además de hemodiálisis en su hogar. Encontró que el uso de Tablo en el hogar es muy intuitivo, lo que le permite dializarse mientras sigue productivo durante el tratamiento.

«La parte en el hogar del estudio con Tablo solo duró ocho semanas, pero fue esclarecedora», dijo. «El sistema es sumamente fácil de instalar y de usar, así que no estaba desperdiciando horas en tareas relativas a la diálisis. Podía trabajar en mi escritorio durante los tratamientos, lo que era maravilloso para mi productividad. El sistema me dio un nuevo nivel de independencia, dada la facilidad de instalación y mantenimiento. Cuando finalizó el estudio y tuvieron que llevarse el Tablo, traté de convencerlos de que no lo hicieran. Realmente odié que se lo llevaran».

Outset comenzará un despliegue controlado para el uso hogareño en lugares seleccionados en los meses venideros, para asegurar el mayor nivel de capacitación y apoyo para los pacientes de Tablo en el hogar. Este programa se equilibrará con la necesidad de proveer a los sistemas de salud, hospitales y clínicas dispositivos para soportar un crecimiento abrupto de la demanda por tratamientos de diálisis impulsada por el COVID-19. Puede encontrarse más información sobre la disponibilidad para pacientes y proveedores en www.outsetmedical.com.

Tablo fue diseñado en Silicon Valley para reducir el costo y la complejidad de la atención de diálisis. Con solo el requisito de un enchufe eléctrico y agua de red para operar, el sistema móvil Tablo libera a pacientes y proveedores de la costosa infraestructura de una clínica. La funcionalidad de la máquina le permite actuar como una clínica de diálisis sobre ruedas. Los datos inalámbricos, la automatización basada en sensores y una pantalla táctil animada hacen que el sistema sea fácil de aprender y de usar. Sistemas de salud y centros médicos líderes de todo EE. UU. usan Tablo para diálisis en hospitales y clínicas, y el Departamento de Salud y Servicios Humanos de los EE. UU. otorgó un contrato para el uso de Tablo en comunidades golpeadas por desastres naturales.

Tecnología galardonada

En el pasado mes de abril, Outset fue uno de los ganadores de la Competencia KidneyX Redesign Dialysis, una asociación entre el Departamento de Salud y Servicios Humanos de los EE. UU. y la Sociedad Americana de Nefrología con el objeto de apoyar estrategias innovadoras para abordar la enfermedad renal. El concepto ganador de Outset enlaza datos de los sensores y los sistemas de automatización exclusivos de Tablo con datos fisiológicos del paciente, con el ojo puesto en generar tratamientos de diálisis personalizados que mejoran los resultados de los pacientes.

El sistema Tablo de Outset también fue reconocido recientemente con un premio Edison Oro en la categoría de experiencia médica del paciente. Los premios Edison honran las innovaciones revolucionarias en la vanguardia del desarrollo, marketing y diseño centrado en las personas de nuevos productos y servicios. Los nominados fueron evaluados por un panel de más de 3,000 ejecutivos de negocios que incluían ganadores anteriores, académicos y líderes en los campos de desarrollo de producto, diseño, ingeniería, ciencia y medicina. Tablo recibió el premio máximo de su categoría, el premio Oro. 

ACERCA DE OUTSET MEDICAL

Outset Medical, con sede en Silicon Valley, está dedicada a la innovación de modelos de servicios impulsados por la tecnología que apuntan a reducir el costo y transformar la experiencia de la atención al paciente. El Sistema Tablo de Outset tiene aprobación de la FDA en entornos de atención aguda, crónica y hogareña. Para obtener más información, visite www.outsetmedical.com y siga a la compañía por Twitter en @OutsetMedical.

CONTACTO GENERAL

www.outsetmedical.com

FUENTE Outset Medical, Inc.

Transmission Control System Market to Reach $58.61 Bn, Globally, by 2026 at 6.3% CAGR: Allied Market Research

Surge in demand for automatic transmission in vehicles and growth in trend of autonomous vehicles propel the growth of the global transmission control system market

PORTLAND, Oregon, April 2, 2020 /PRNewswire/ — Allied Market Research published a report, titled, «Transmission Control System Market by Installation (Integrated and Stand-alone) and Vehicle…

Surge in demand for automatic transmission in vehicles and growth in trend of autonomous vehicles propel the growth of the global transmission control system market

PORTLAND, Oregon, April 2, 2020 /PRNewswire/ — Allied Market Research published a report, titled, «Transmission Control System Market by Installation (Integrated and Stand-alone) and Vehicle Type (Passenger Vehicle, Commercial Vehicle, and Electric vehicle): Global Opportunity Analysis and Industry Forecast, 2019–2026.» According to the report, the global transmission control system industry garnered $36.30 billion in 2018, and is expected to generate $58.61 billion by 2026, growing at a CAGR of 6.3% from 2019 to 2026.

Allied Market Research Logo

Prime determinants of growth

Increase in demand for automatic transmission in vehicles and rise in trend of autonomous vehicles drive the growth of the global transmission control system market. However, high cost of transmission control system restrains the market growth. On the other hand, production of active shift control transmission is expected to create new opportunities in the market.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6348

The integrated segment to continue its lead position during the forecast period

Based on installation, the integrated segment held more than half of the total share of the global transmission control system market in 2018, and is expected to continue its lead position during the forecast period. This is due to electronic set and electrical components such as transmission control unit, sensors, solenoids, and hydraulic valve body are integrated into a single module which makes it the largest segment in installation. However, the stand-alone segment would witness the highest CAGR of 7.1% from 2019 to 2026, as it is inexpensive and easy-to -use, and offers benefits such as reliability and high performance.

The passenger vehicle segment maintains its lead in terms of revenue by 2026

Based on vehicle type, the passenger vehicle segment held the largest market share of the global transmission control system market in 2018, accounting for nearly two-third of the total share, and will maintain its leadership position in terms of revenue throughout the forecast period. Rise in infrastructural development has fueled the adoption of passenger cars, and propelled the growth of the segment. However, the electric vehicle segment is estimated to register the fastest CAGR of 14.9% from 2019 to 2026. Increase in demand for fuel efficient vehicle and government initiatives for adoption of electric vehicle makes this segment the fastest growing.

Asia-Pacific to grow at the fastest rate

Based on region, Asia-Pacific contributed to the highest market share in terms of revenue, contributing to more than two-fifths of the global transmission control system market in 2018, and is estimated to continue its dominant share during the forecast period. In addition, the region is estimated to witness the highest CAGR of 7.6% from 2019 to 2026. Rising population, government policies for emission control and increase in demand for Automobiles, augmented the growth of the region.

For purchase inquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6348

Leading market players

  • EATON
  • Infineon Technologies AG
  • Robert Bosch GMBH
  • ZF Friedrichshafen AG
  • Delphi Technologies
  • DENSO Corporation
  • Dana Limited
  • Allison Transmission Inc.
  • Borgwarner Inc.
  • Continental AG

Avenue | the Market Research Library Access

Avenue, a user-based library of global market report database, provides comprehensive reports pertaining to the world’s largest emerging markets. It further offers e-access to all the available industry reports just in a jiffy. Avenue is a premium subscription-based model that serves as an informative solution on which the world-leading companies can rely on.

Avenue is a premium subscription-based model that serves as an informative solution on which the world-leading companies can rely on.

Sign up and start using your 14-day free trial: https://www.alliedmarketresearch.com/avenueTrial

Similar Reports:

Autonomous Vehicle Market Expected to Reach $54.23 Billion, by 2026

Passenger Car Accessories Maintenance, After Sales Services (Aftermarket) Market worth $248.41 Bn by 2026

Electric Vehicle Market Forecasted to Value $561,299.8 Million by 2025

Autonomous Emergency Braking System Market to Reach $67.67 Bn by 2023, with Top Manufacturer

Pre-book Offer 12% Discount:

Automotive Repair and Service Market

Automotive Digital Cockpit Market

Advanced Gear Shifter System Market

About us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of «Market Research Reports» and «Business Intelligence Solutions.» AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact us:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com

Web: www.alliedmarketresearch.com

Follow us on: www.linkedin.com/company/allied-market-research 

Allied Market Research Blog: blog.alliedmarketresearch.com   

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg 

Smart Windows Market to Garner $8.97 Bn, Globally, by 2026 at 11.4% CAGR, Says Allied Market Research

– Surge in demand for products manufactured using smart glass in the construction sector and its influence on the automobile industry have boosted the growth of the global smart windows market.

PORTLAND, Oregon, April 2, 2020 /PRNewswire/ —  Allied Market Research recently published a report, titled, «Smart Windows Market by Technology (Suspended…

– Surge in demand for products manufactured using smart glass in the construction sector and its influence on the automobile industry have boosted the growth of the global smart windows market.

PORTLAND, Oregon, April 2, 2020 /PRNewswire/ —  Allied Market Research recently published a report, titled, «Smart Windows Market by Technology (Suspended Particle Device Light Modulator, Polymer Dispersed Liquid Crystal Devices Scanner, and Electro Chromic), Type (OLED Glass, Self-Dimming Window, and Self-Repairing), Application (Residential, Commercial, Industrial, and Transport): Global Opportunity Analysis and Industry Forecast, 2019-2026″. According to the report, the global smart windows industry was pegged at $4.22 billion in 2019, and is projected to reach $8.97 billion by 2026, growing at a CAGR of 11.4% from 2019 to 2026.

Allied Market Research

Driving factors for the market

Surge in demand for products manufactured using smart glass in the construction sector and its influence on the automobile industry coupled with rigorous government regulations to control risk-oriented incidents have boosted the growth of the global smart windows market. However, lack of awareness on long-term benefits hampers the market growth. On the contrary, lowing prices of advance materials is expected to create lucrative opportunities in the near future.

Download Sample Report @ https://www.alliedmarketresearch.com/request-sample/6415 

OLED glass segment dominated the market

By type, the OLED glass segment held the largest share in 2019, accounting for more than two-thirds of the market, owing to its various advantages over conventional display technologies such as being light in weight and its flexibility. However, the self-repairing segment is expected to register the highest CAGR of 14.7% during the forecast period, due to its application in harsh environments such as industrial, automotive, construction, and manufacturing.

Commercial segment to portray the fastest CAGR through 2026

The commercial segment is expected to manifest the fastest CAGR of 14.0% from 2019 to 2026, due to the high adoption of intelligent solutions in the commercial sector to operate automatically and conserve energy and reducing human efforts. However, the transport segment held the largest share in 2019, contributing to nearly half of the market. This is due to increase in demand for smart windows in commercial vehicles, trains, passenger vehicles.

North America region held the lion’s share

The market across North America accounted for the largest share in 2019, holding nearly one-third of the total revenue. This is due to the presence of the largest residential and commercial sector that demands smart glass in their properties. However, the market across Europe is projected to portray the highest CAGR of 13.3% during the forecast period, as it is a multi-purpose building material and is widely used by architects, engineers, and designers.

To Explore More, Make Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/6415

Major market players

  • Pleotint LLC
  • Research Frontiers Inc
  • SAGE Electrochromics, Inc
  • Gentex Corporation
  • Polytronix, Inc
  • ChromoGenics
  • Stellaris Corporation
  • Smart Windows Colorado
  • Innovative Glass Corporation
  • View, Inc.

Access AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) @ https://www.alliedmarketresearch.com/library-access

Avenue is a user-based library of global market report database, provides comprehensive reports pertaining to the world’s largest emerging markets. It further offers e-access to all the available industry reports just in a jiffy. By offering core business insights on the varied industries, economies, and end users worldwide, Avenue ensures that the registered members get an easy as well as single gateway to their all-inclusive requirements.

Avenue Library Subscription | Request for 14 days free trial of before buying:

https://www.alliedmarketresearch.com/avenue/trial/starter

Similar Reports:

Smartwatch Market Expected to Reach $31.07 Billion By 2025

Smart Glass and Smart Window Market Projected to Hit $6.9 Billion By 2022

Smart Exoskeleton Market Anticipated to Grow $1,896.8 Million By 2025

Smart Speaker Market Expected to Grow $23.32 Billion By 2025

Smartphone 3D Camera Market Projected to Garner $9,280 Million By 2025

Smart Robot Market Anticipated to Reach $17.56 Billion By 2025

Pre-Book Now with 10% Discount:

Smart Battery Charger Market: Global Opportunity Analysis and Industry Forecast 2019-2026

Smart Meters Market: Global Opportunity Analysis and Industry Forecast 2020-2027

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of «Market Research Reports» and «Business Intelligence Solutions.» AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com 

Follow Us on LinkedIn and Twitter 

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg 

El test rápido de IgG e IgM para COVID-19 de COVID Care ha recibido autorización según las pautas de la EUA de la FDA para su distribución inmediata entre profesionales médicos

LOS ÁNGELES, 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — Molecule Holdings tiene el gran placer de anunciar que ya se encuentra suministrando kits de prueba Rapid COVID-19 aprobados por la FDA a profesionales médicos, socorristas y…

LOS ÁNGELES, 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — Molecule Holdings tiene el gran placer de anunciar que ya se encuentra suministrando kits de prueba Rapid COVID-19 aprobados por la FDA a profesionales médicos, socorristas y fuerzas del orden. Este test detecta anticuerpos IgG e IgM para SARS-CoV-2 en la sangre humana. El test Covid Care Rapid tiene una calificación de sensibilidad clínica de 91% y de especificidad clínica de 99%.

RESULTADOS EN SOLO 5 MINUTOS

Los profesionales médicos son inflexibles en cuanto a la importancia fundamental de tener acceso a pruebas rápidas en el punto de atención que sean simples y asequibles. La tecnología de prueba de PCR requiere varios días para producir resultados y no es escalable ni resulta una solución asequible para responder a la extensión de las necesidades de prueba de COVID-19 de la comunidad y el mundo.

Los kits de prueba COVID Care están aprobados por la FDA bajo la Ley de Uso de Emergencia (Emergency Use Act, EUA) y proceden de Pinnacle BioLabs, un laboratorio de Tennessee registrado en la FDA. Se fabrican en una planta con certificación ISO-13485. Los kits han sido sometidos a considerables pruebas clínicas preliminares y los resultados se recibieron…

Los test COVID Care brindan resultados con una especificidad de diagnóstico superior al 90%.

Las pruebas con el test COVID Care son sencillas y se parecen a las que usan los diabéticos para verificar su nivel de azúcar en la sangre.

Simplemente «pinche» un dedo con la lanceta incluida, deje caer 2 gotas de sangre en el cartucho de prueba incluido, deje caer 2 gotas de solución de prueba en el cartucho y espere unos 5 minutos para obtener los resultados. La interpretación de los resultados es un proceso muy sencillo.

Foto – https://mma.prnewswire.com/media/1139467/COVID_19_Testing_Kit.jpg

 

FUENTE Molecule Holdings

El test rápido de IgG e IgM para COVID-19 de COVID Care ha recibido autorización según las pautas de la EUA de la FDA para su distribución inmediata entre profesionales médicos

LOS ÁNGELES, 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — Molecule Holdings tiene el gran placer de anunciar que ya se encuentra suministrando kits de prueba Rapid COVID-19 aprobados por la FDA a profesionales médicos, socorristas y…

LOS ÁNGELES, 2 de abril de 2020 /PRNewswire-HISPANIC PR WIRE/ — Molecule Holdings tiene el gran placer de anunciar que ya se encuentra suministrando kits de prueba Rapid COVID-19 aprobados por la FDA a profesionales médicos, socorristas y fuerzas del orden. Este test detecta anticuerpos IgG e IgM para SARS-CoV-2 en la sangre humana. El test Covid Care Rapid tiene una calificación de sensibilidad clínica de 91% y de especificidad clínica de 99%.

RESULTADOS EN SOLO 5 MINUTOS

Los profesionales médicos son inflexibles en cuanto a la importancia fundamental de tener acceso a pruebas rápidas en el punto de atención que sean simples y asequibles. La tecnología de prueba de PCR requiere varios días para producir resultados y no es escalable ni resulta una solución asequible para responder a la extensión de las necesidades de prueba de COVID-19 de la comunidad y el mundo.

Los kits de prueba COVID Care están aprobados por la FDA bajo la Ley de Uso de Emergencia (Emergency Use Act, EUA) y proceden de Pinnacle BioLabs, un laboratorio de Tennessee registrado en la FDA. Se fabrican en una planta con certificación ISO-13485. Los kits han sido sometidos a considerables pruebas clínicas preliminares y los resultados se recibieron…

Los test COVID Care brindan resultados con una especificidad de diagnóstico superior al 90%.

Las pruebas con el test COVID Care son sencillas y se parecen a las que usan los diabéticos para verificar su nivel de azúcar en la sangre.

Simplemente «pinche» un dedo con la lanceta incluida, deje caer 2 gotas de sangre en el cartucho de prueba incluido, deje caer 2 gotas de solución de prueba en el cartucho y espere unos 5 minutos para obtener los resultados. La interpretación de los resultados es un proceso muy sencillo.

Foto – https://mma.prnewswire.com/media/1139467/COVID_19_Testing_Kit.jpg

 

FUENTE Molecule Holdings

Visiongain Publishes Automotive Fuel Cell Market 2020-2030 Report

LONDON, April 2, 2020 /PRNewswire/ — Market and Volume Forecasts by Electrolyte Type (PEMFC, PAFC, SOFC, DMFC and Others), by Component Type (Power Output Stack, Power Output Processor, Power Conditioner and Others), Power Output (200 Kw Power Output), Vehicle Type (Passenger Cars, Light Commercial Vehicles and Heavy Commercial Vehicles) with Regional and National Market Analysis and Financial Analysis of Leading Companies

<div id="prni_dvprnejpg995cleft" style="WIDTH: 100%; TEXT-ALIGN:…

LONDON, April 2, 2020 /PRNewswire/ — Market and Volume Forecasts by Electrolyte Type (PEMFC, PAFC, SOFC, DMFC and Others), by Component Type (Power Output Stack, Power Output Processor, Power Conditioner and Others), Power Output (200 Kw Power Output), Vehicle Type (Passenger Cars, Light Commercial Vehicles and Heavy Commercial Vehicles) with Regional and National Market Analysis and Financial Analysis of Leading Companies

Visiongain Logo

The global automotive fuel cell market is expected to grow by exponential growth rate of 39.6% over the forecast period from 2020 to 2030. The market is driven mainly by the advantages provided by fuel cell vehicles, such as improved fuel efficiency and enhanced driving range, rapid refuelling, decreased petroleum dependency and no greenhouse gas emissions and air pollutants. Growing concerns about alarming rates of pollution have resulted in a change in the trend towards clean fuels and green technologies to decrease the carbon footprint efficiently. Over the previous few years, this has had a positive impact on demand for fuel cells. Increasing demand in the automotive and transportation industries for fuel cell vehicles and public initiatives to build hydrogen infrastructure will further increase the worldwide market.

By electrolyte type, PEMFC is expected to be the largest and fastest growing segment in the overall fuel cell market in 2019 due to its properties including small size, high-power density, high efficiency, light weight, and appropriate operating temperature.

Asia Pacific is expected to be the largest market for automotive fuel cell. Rising production and consumption of fuel cell vehicles, investment in hydrogen infrastructure, and growing environmental and health concern; all these factors are expected to propel the automotive fuel cell demand in APAC region. The growth of middle-class population and standard of living in the region, particularly in China and India, is driving the sales of fuel cells vehicles which further supported to the overall market demand.

Download samples here:

https://www.visiongain.com/report/automotive-fuel-cell-market-report-2020-2030/#download_sampe_div

Leading companies featured in the Automotive Fuel Cell Market Report 2020-2030 report include Automotive Fuel Cell Cooperation, Ballard Power Systems, Ceramic Fuel Cells Ltd, Ceres Power, Delphi Technologies, Doosan Fuel Cell America, Hydrogenics, ITM Power, Nedstack, NUVERA among others. Mergers & acquisitions and joint ventures constitute some of the industry players’ common strategies for reducing product price overall and maintaining extremely competitive conditions. In order to guarantee continued raw material supplies and ease of installation services, many actors in the sector create alliances with raw material providers and third-party installers.

The comprehensive report provides market estimates and forecasts for leading domestic markets across the world for the period from 2020 to 2030. In addition, the report includes dedicated leading companies covering 10 leading fuel cell producers.

The report on the Automotive Fuel Cell Market Report 2020-2030 will appreciate anyone who wants to better understand the market in various end use industries. It will be useful for companies that want to better understand the part of the market in which they are already involved or those that want to enter or expand into another regional or technical part of the Automotive Fuel Cell industry.

Visiongain’s timely report reveals how best to compete in this profitable market space and maximize your company’s potential.

To find out more about this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/automotive-fuel-cell-market-report-2020-2030/

This report addresses the pertinent issues:
– Where are the most lucrative market prospects?
– Who are the leadings companies and what does the competitive landscape look like?
– What are the regional, technical and regulatory barriers to market entry?
– What are the technological issues and roadmap driving the market?
– Why is the market prospering and how can you fully exploit this?
– When will the market fully mature and why?

Research and Analysis Highlights

335 Tables, Charts and Graphs Illustrating the Global Automotive Fuel Cell Market Prospects

Market Segmentation 2020-2030:

The global automotive fuel cell market is segmented on the basis of electrolyte type, component types, power output, vehicle type, and geography.

Automotive Fuel Cell Submarket Forecasts by Electrolyte Type Covering the Period 2020-2030 ($M & Volume)
– PEMFC Market Forecast 2020-2030 ($M & Volume)
– PAFC Market Forecast 2020-2030 ($M & Volume)
– SOFC Market Forecast 2020-2030 ($M & Volume)
– DMFC Market Forecast 2020-2030 ($M & Volume)
– Other Electrolyte Type Market Forecast 2020-2030 ($M & Volume)

Automotive Fuel Cell Submarket Forecasts by Component Types from 2020-2030 ($M & Volume)
– Fuel Stack Market Forecast 2020-2030 ($M & Volume)
– Fuel Processor Market Forecast 2020-2030 ($M & Volume)
– Power Conditioner Market Forecast 2020-2030 ($M & Volume)
– Other Component Types Market Forecast 2020-2030 ($M & Volume)

Automotive Fuel Cell Submarket Forecasts by Power Output from 2020-2030 ($M & Volume)
– <100 Kw Power Output Market Forecast 2020-2030 ($M & Volume)
– 100–200 Kw Power Output Market Forecast 2020-2030 ($M & Volume)
– >200 Kw Power Output Market Forecast 2020-2030 ($M & Volume)

Automotive Fuel Cell Submarket Forecasts by Vehicle Type from 2020-2030 ($M & Volume)
– Passenger Cars Market Forecast 2020-2030 ($M & Volume)
– Light Commercial Vehicles Market Forecast 2020-2030 ($M & Volume)
– Heavy Commercial Vehicles Market Forecast 2020-2030 ($M & Volume)

Regional Automotive Fuel Cell Market Forecasts 2020-2030:

North America Automotive Fuel Cell Forecast 2020-2030 ($M & Volume)
– US Market Forecast 2020-2030 ($M & Volume)
– Canada Market Forecast 2020-2030 ($M & Volume)
– Mexico Market Forecast 2020-2030 ($M & Volume)

South America Automotive Fuel Cell Forecast 2020-2030 ($M & Volume)
– Brazil Market Forecast 2020-2030 ($M & Volume)
– Argentina Market Forecast 2020-2030 ($M & Volume)
– Colombia Market Forecast 2020-2030 ($M & Volume)
– Rest of South America Market Forecast 2020-2030 ($M & Volume)

Europe Automotive Fuel Cell Forecast 2020-2030 ($M & Volume)
– Germany Market Forecast 2020-2030 ($M & Volume)
– France Market Forecast 2020-2030 ($M & Volume)
– UK Market Forecast 2020-2030 ($M & Volume)
– Czech Republic Market Forecast 2020-2030 ($M & Volume)
– Spain Market Forecast 2020-2030 ($M & Volume)
– Turkey Market Forecast 2020-2030 ($M & Volume)
– Russia Market Forecast 2020-2030 ($M & Volume)
– Slovakia Market Forecast 2020-2030 ($M & Volume)
– Italy Market Forecast 2020-2030 ($M & Volume)
– Poland Market Forecast 2020-2030 ($M & Volume)
– Rest of Europe Market Forecast 2020-2030 ($M & Volume)

Asia Pacific Automotive Fuel Cell Forecast 2020-2030 ($M & Volume)
– China Market Forecast 2020-2030 ($M & Volume)
– Japan Market Forecast 2020-2030 ($M & Volume)
– India Market Forecast 2020-2030 ($M & Volume)
– South Korea Market Forecast 2020-2030 ($M & Volume)
– Thailand Market Forecast 2020-2030 ($M & Volume)
– Malaysia Market Forecast 2020-2030 ($M & Volume)
– Indonesia Market Forecast 2020-2030 ($M & Volume)
– Taiwan Market Forecast 2020-2030 ($M & Volume)
– Rest of Asia Pacific Market Forecast 2020-2030 ($M & Volume)

Rest of the World Automotive Fuel Cell Forecast 2020-2030 ($M & Volume)
– Middle East Market Forecast 2020-2030 ($M & Volume)
– Africa Market Forecast 2020-2030 ($M & Volume)

Profiles of 10 Leading Companies, Involved in Automotive Fuel Cell Market
– Automotive Fuel Cell Cooperation
– Ballard Power Systems
– Ceramic Fuel Cells Ltd
– Ceres Power
– Delphi Technologies
– Doosan Fuel Cell America
– Hydrogenics
– ITM Power
– Nedstack
– Nuvera

SWOT And Porter’s Five Forces Analysis

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

AFCC
Audi
Automotive Fuel Cell Cooperation
Ballard Power Systems
BMW
Ceramic Fuel Cells Ltd
Ceres Power
Daimler
Delphi Technologies
Doosan Fuel Cell America
General Motors
Honda
Hydrogenics
Hyundai
ITM Power
MAN
Nedstack
Nissan
Nuvera
Panasonic
Plug Power
Toshiba
Toyota
Volvo

To discuss this report please e-mail Sara Peerun on sara.peerun@visiongain.com

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Tablo® Hemodialysis System Receives FDA Clearance for Home Dialysis

SAN JOSE, Calif., April 2, 2020 /PRNewswire-HISPANIC PR WIRE/ — Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced the Food and Drug Administration (FDA) cleared the Tablo Hemodialysis System for patient use in the home. The new home clearance expands Tablo’s existing labeled indication for use in acute and chronic care facilities, which for the first time enables healthcare providers the same dialysis machine…

SAN JOSE, Calif., April 2, 2020 /PRNewswire-HISPANIC PR WIRE/ — Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced the Food and Drug Administration (FDA) cleared the Tablo Hemodialysis System for patient use in the home. The new home clearance expands Tablo’s existing labeled indication for use in acute and chronic care facilities, which for the first time enables healthcare providers the same dialysis machine from the ICU to the home. 

Tablo enters the market at a critical time in the midst of the COVID-19 pandemic and renewed national focus on home dialysis for improving patient outcomes while lowering cost.  In mid-2019, President Trump and United States Department of Health and Human Services Secretary Alex Azar announced an Executive Order to help Americans with kidney failure.  A major component of the policy was ensuring 80% of all new dialysis patients start therapy at home or get transplanted by 2025.  The emergence of COVID-19 further heightens the urgency for giving current in-center dialysis patients the option to treat at home.

«Tablo was designed to simplify dialysis, making it easier and more accessible for patients to take advantage of the safety, convenience and flexibility of dialyzing at home,» said Outset Medical Chief Executive Officer, Leslie Trigg.  «We are proud to offer them this new, life-enhancing option, particularly in light of the COVID-19 related challenges dialysis patients and providers are experiencing.»

Currently, more than 500,000 Americans undergo dialysis treatments three or more times each week, typically lasting four hours per treatment.  Approximately 100,000 new patients start treatment annually.  Yet only 12% receive it at home where they’re more comfortable, productive and empowered. 

POSITIVE TRIAL RESULTS

A prospective, multicenter, home hemodialysis trial with 30 patients was completed in 2019 and confirmed the Tablo system is safe and effective for home use.  The results were published in November 2019 in Hemodialysis International.

Troy Plumb, M.D., the principal study investigator and the Division Chief of Nephrology and Associate Professor of Medicine at the University of Nebraska Medical Center College of Medicine in Omaha, said, «My patients, colleagues and I are excited for Tablo to be available for home use.  The trial made it clear the system is easy to learn and performs well in the home environment.  I believe that Tablo will open up opportunities for patients to pursue home hemodialysis and take more control over their lives and care.»

One of those patients is 62-year-old Texas resident and technology consultant Richard Crawford.  He has had a kidney transplant that lasted 17 years and is currently on a transplant list.  Over the years, he has had thousands of dialysis treatments at various centers as well as on home hemodialysis.  He found using Tablo at home to be very intuitive, allowing him to dialyze while remaining productive during treatment.

«The home part of the Tablo trial only lasted eight weeks, but was eye opening,» he said. «The system is extremely easy to set up and use, so I wasn’t wasting hours on dialysis-related tasks.  I was able to work at my desk during treatments, which was wonderful for my productivity.  The system provided me with a new level of independence due to the ease of setup and maintenance.  «When the trial ended and they had to pick up the Tablo, I tried talking them out of it.  I really hated seeing it go.»

Outset will begin a controlled rollout for home use at select sites over the coming months to ensure the highest level of training and support for Tablo home patients. This program will be balanced with the need to supply health systems, hospitals, and clinics with devices to support a surge of demand for dialysis treatments driven by COVID-19.  More information about availability for patients and providers can be found at www.outsetmedical.com.

Tablo was designed in Silicon Valley to reduce the cost and complexity of dialysis care. Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from expensive clinic infrastructure.  The machine’s functionality enables it to serve as a dialysis clinic on wheels. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use.  Leading health systems and medical centers across the U.S. use Tablo for hospital and clinic dialysis, and the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters.

Award Winning Technology

Last April, Outset was a winner of the KidneyX Redesign Dialysis Competition, a partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease. Outset’s winning concept marries data from Tablo’s unique sensors and automation systems with physiologic data from the patient with an eye toward creating personalized dialysis treatments that improve patient outcomes.

Outset’s Tablo System was also recently recognized with a Gold Edison Award in the medical patient experience category. The Edison Awards honor game-changing innovations at the forefront of new product and service development, marketing and human-centered design. Nominees were judged by a panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of product development, design, engineering, science and medicine. Tablo received the top prize in its category, the Gold Award. 

ABOUT OUTSET MEDICAL

Silicon Valley-based Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is FDA-cleared for use in acute, chronic care and home settings.  For more information visit www.outsetmedical.com and follow the company on Twitter at @OutsetMedical.

GENERAL CONTACT

www.outsetmedical.com

SOURCE Outset Medical, Inc.